Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.

MLA

Okumura, Hiroyuki, et al. “Cost-Effectiveness Analysis of Enzalutamide for Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Japan.” Japanese Journal of Clinical Oncology, vol. 51, no. 8, Aug. 2021, pp. 1319–29. EBSCOhost, https://doi.org/10.1093/jjco/hyab071.

APA

Okumura, H., Inoue, S., Naidoo, S., Holmstrom, S., & Akaza, H. (2021). Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan. Japanese Journal of Clinical Oncology, 51(8), 1319–1329. https://doi.org/10.1093/jjco/hyab071

Chicago

Okumura, Hiroyuki, Sachie Inoue, Shevani Naidoo, Stefan Holmstrom, and Hideyuki Akaza. 2021. “Cost-Effectiveness Analysis of Enzalutamide for Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Japan.” Japanese Journal of Clinical Oncology 51 (8): 1319–29. doi:10.1093/jjco/hyab071.